Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? - A Case Report.

Chiara JeizinerSamuel S AllemannHersberger KurtHenriette E Meyer Zu Schwabedissen

Published in: Pharmacogenomics and personalized medicine (2022)

The MTX pathway is complex, which makes the interpretation of genetic variants affecting metabolism challenging. A reactive PGx panel test was applicable to explain ADRs experienced during MTX treatment for a patient with RA. However, the clinical utility of PGx-guided MTX treatment in a primary care setting is still limited. In order to base a recommendation for MTX on PGx data, we need genome-wide association studies, large prospective multicenter studies and PGx studies, which analyze different multi-gene haplotypes and gene-drug-drug interactions for MTX.

Keyphrases

rheumatoid arthritis
primary care
low dose
high dose
case control
genome wide association
genome wide
electronic health record
clinical trial
combination therapy
emergency department
ankylosing spondylitis
replacement therapy
big data
transcription factor
interstitial lung disease
idiopathic pulmonary fibrosis